期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (4)
PurposeThis manuscript reports on the occurrence of early and frequent erythrocytosis in advanced hepatocellular carcinoma (HCC) patients treated with......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (6)
PurposeAdverse effects following fluoropyrimidine-based chemotherapy regimens are common. However, there are no current accepted diagnostic markers fo......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 92 (1)
PurposeCisplatin resistance is the major obstacle in the clinical treatment of ovarian cancer patients. Molecular mechanisms of cisplatin resistance a......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; ()
PurposeWe report the case of an adult patient diagnosed with Hodgkin's lymphoma who was scheduled for Pembrolizumab after failure of standard therapy.......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; ()
PurposeSUVN-1105 is a novel formulation of abiraterone acetate which was developed to demonstrate improved bioavailability, compared to Zytiga and Yon......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 92 (3)
PurposeRhabdomyolysis, which is primarily characterized by serum creatine kinase (CK) elevation, is a potentially fatal disease, and it can occur in a......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; ()
PurposeChemotherapy for the hemodialysis (HD) patient is a challenging situation because it requires special considerations including dose modificatio......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; ()
PurposePazopanib is known to cause liver toxicity. A relationship between pazopanib exposure and alanine transaminase elevations has been described in......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (5)
BackgroundFluoropyrimidines (FPs) form still nowadays the backbone of chemotherapic schemes in colorectal cancer (CRC). Inter-patient variability of t......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (5)
Purpose The objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 92 (1)
PurposeFor patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvaluma......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (1)
PurposeAdenosine triphosphate (ATP)-binding cassette (ABC) transporters play an important role in the response to methotrexate (MTX). In this study, w......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (2)
Purpose Colorectal cancer (CRC) is the second most common cause of cancer death worldwide. Trifluridine (FTD) remained at higher concentrations longer......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 91 (4)
PurposeThere is no consensus on the safety and effectiveness of adjuvant chemotherapy for patients with stage III colorectal cancer (CRC) aged >= 8......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023; 92 (2)
Aberrant alternative splicing (AS) events are frequently observed in lung cancer, which can be attributed to aberrant gene AS, alterations in splicing......
